Cargando…

Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease

PURPOSE: We evaluate a matrix metalloproteinase-9 (MMP-9) point-of-care immunoassay (InflammaDry) as a prognostic tool for topical cyclosporine treatment. METHODS: A total of 20 healthy subjects and 40 patients meeting >3 dry eye disease (DED) criteria (ocular surface disease index [OSDI] score ≥...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jae Yong, Kim, Bum Gi, Kim, Jae Suk, Hwang, Je Hyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Association for Research in Vision and Ophthalmology 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205558/ https://www.ncbi.nlm.nih.gov/pubmed/30386683 http://dx.doi.org/10.1167/tvst.7.5.31

Ejemplares similares

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Dichotomous versus 5-scale grading system for the interpretation of the point-of-care immunoassay for tear matrix metalloproteinase-9 in dry eye
por: Oh, Ja Young, et al.
Publicado: (2023)

Comparative Evaluation of Matrix Metalloproteinase-9 Immunoassay and Tear Osmolarity Measurement for Diagnosing Severity of Dry Eye Disease
por: Choi, Moonjung, et al.
Publicado: (2023)

Comparison of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye
por: So, Ha Rim, et al.
Publicado: (2023)

Novel point-of-care biomarkers of the dry anophthalmic socket syndrome: tear film osmolarity and matrix metalloproteinase 9 immunoassay
por: Rokohl, Alexander C., et al.
Publicado: (2022)

Short-Term Therapeutic Effects of Topical Corticosteroids on Refractory Dry Eye Disease: Clinical Usefulness of Matrix Metalloproteinase 9 Testing as a Response Prediction Marker
por: Ryu, Kyung Jae, et al.
Publicado: (2021)

Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
por: Singla, Shaveta, et al.
Publicado: (2019)

The Correlation between Matrix Metalloproteinase-9 Point-of-Care Immunoassay, Tear Film Osmolarity, and Ocular Surface Parameters
por: Kang, Min-Ji, et al.
Publicado: (2022)

In vitro validation of the tear matrix metalloproteinase 9 in-situ immunoassay
por: Bang, Seung Pil, et al.
Publicado: (2020)

Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye
por: Moon, Jun Woong, et al.
Publicado: (2007)

Assessment of reliability and validity of the 5-scale grading system of the point-of-care immunoassay for tear matrix metalloproteinase-9
por: Kim, Minjeong, et al.
Publicado: (2021)

Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

Association of tear matrix metalloproteinase 9 immunoassay with signs and symptoms of dry eye disease: A cross-sectional study using qualitative, semiquantitative, and quantitative strategies
por: Lee, You Hyun, et al.
Publicado: (2021)

Importance of tear volume for positivity of tear matrix metalloproteinase-9 immunoassay
por: Jun, Jong Hwa, et al.
Publicado: (2020)

Cyclosporine Amicellar delivery system for dry eyes
por: Kang, Han, et al.
Publicado: (2016)

Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury
por: Jadidi, Khosrow, et al.
Publicado: (2014)

Incidence and management of symptomatic dry eye related to LASIK for myopia, with topical cyclosporine A
por: Kanellopoulos, Anastasios John
Publicado: (2019)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian, Cynthia, et al.
Publicado: (2021)

Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
por: Park, Chang Hyun, et al.
Publicado: (2019)

Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation
por: Mullick, Ritika, et al.
Publicado: (2021)

Efficacy and safety of using topical cyclosporine A for treatment of moderate to severe dry eye disease
por: Othman, Tageldin M., et al.
Publicado: (2018)

Treatment of chronic dry eye: focus on cyclosporine
por: Kymionis, George D, et al.
Publicado: (2008)

Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea
por: Reviglio, Victor E, et al.
Publicado: (2003)

Effectiveness of Topical Cyclosporin-A 0.1% Compared to Combined Topical Cyclosporin-A 0.1% with Topical Sodium Hyaluronate on Interleukin-6 Levels in the Tears of Patients with Dry Eye Disease
por: Priani, Desti, et al.
Publicado: (2023)

Retraction Note: Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
por: Park, Chang Hyun, et al.
Publicado: (2020)

A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome
por: Lee, Ji Eun, et al.
Publicado: (2022)

An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease
por: Tuan, Hsin-I, et al.
Publicado: (2020)

Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13
por: Kim, Yeoun-Hee, et al.
Publicado: (2017)

Comparison of Consecutive Therapeutic Effects of Nanoemulsion and Emulsion Cyclosporin in Dry Eye Patients after Short-Term Treatment with Topical Fluorometholone
por: Choi, Yeon Sun, et al.
Publicado: (2022)

Therapeutic Potential of the Molecular Chaperone and Matrix Metalloproteinase Inhibitor Clusterin for Dry Eye
por: Fini, M. Elizabeth, et al.
Publicado: (2020)

Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye
por: Schultz, Clyde
Publicado: (2014)

Comparison of Treatment Effect and Tolerance of the Topical Application of Mizoribine and Cyclosporine A in a Mouse Dry Eye Model
por: Lin, Xiang, et al.
Publicado: (2020)

Point of care diagnosis of dry eye disease with a sensitive immunoassay for dual biomarker detection
por: Zhang, Sydney, et al.
Publicado: (2022)

High Levels of 17β-Estradiol Are Associated with Increased Matrix Metalloproteinase-2 and Metalloproteinase-9 Activity in Tears of Postmenopausal Women with Dry Eye
por: Shen, Guanglin, et al.
Publicado: (2016)

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery
por: Yavuz, Burçin, et al.
Publicado: (2012)

The Effects of Fisetin on Cyclosporine-Treated Dry Eye Disease in Dogs
por: Krajčíková, Kristína, et al.
Publicado: (2023)

Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndrome
por: Voigt, Jeffrey
Publicado: (2020)

Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model
por: Bang, Seung Pil, et al.
Publicado: (2019)

Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery
por: Lee, Jang Hoon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_latecghhq6b6idj6jlmpki7mlr